Society of Utah Medical Oncology

Welcome

Our primary mission is to promote the highest professional standards of oncology practice in the state of Utah; to study, research and exchange information, leading to improvement in the practice of hematology; to support and further oncology education; and to monitor and respond to appropriate legislative and regulatory concerns of the membership.

We encourage all oncology professionals to find out more about us and become a member of our growing community.


Membership has its benefits.  Click below to find out more.

Join Today

Report: Progress in Global Cancer Fight is Not Only Possible, but Achievable
The Cancer Atlas, 3rd edition, a comprehensive global overview of cancer around the globe, concludes that progress in the fight against cancer is not only possible, but achievable.

Find out more
CMS to Collect 340B Drug Cost Information

The CMS issued a notice on September 26th that it will collect information from hospitals participating in the 340B drug discount program about the prices they pay for eligible drugs.

Click here for more

Cancer Drugs Account for 27% of All New Drug Approvals in the US
Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010, a dramatic increase from the 4% share of the 1980s, a newly completed analysis from the Tufts Center for the Study of Drug Development shows.

Click here for more

New Technology Add-on Payment: Impact on CAR T-cell Therapy Reimbursement
On August 2, the Centers for Medicare & Medicaid Services (CMS) released the Hospital Inpatient Prospective Payment System (IPPS) final rule for fiscal year (FY) 2020.

Click here for more.

CMS Expands CAR T-cell Therapy Coverage for Medicare Beneficiaries
The Centers for Medicare & Medicaid Services (CMS) announced that Medicare will now cover all Food and Drug Administration-approved Chimeric Antigen Receptor T-cell (CAR T-cell) therapy delivered in inpatient facilities.  This nationwide Medicare coverage increase for CAR T-cell therapy also opens the door for patients to receive treatment in outpatient health care facilities that are enrolled in FDS risk evaluation and mitigation strategies with expertise in delivering cellular therapies, and covers CAR T-cell therapy for off-label uses that are recommended by CMS-approved compendia.

Read more here

Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study
State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.

Click here for more.
CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials

Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments

Click here for more

 

Upcoming Events


 

New ASCO Policy Brief: Co-Pay Accumulators and Co-pay Maximizers
Co-pay accumulators and co-pay maximizers have been an area of concern amongst State Affiliate Council members.  ASCO has created a new informational policy brief to help explain these programs and provide guidance regarding its position as an organization.  The brief can be accessed by clicking below.

Click here for more information

United Health and Optum 'Uniting Care and Coverage' in New Model
UnitedHealth Group and its Optum medical care provider business are rolling out a combined package of medical care and health insurance as they meld health benefits with the provision of healthcare services.

Find out more

New Survey Seeks Provider Input on Clinical Trial Enrollment
ASCO is participating in a joint initiative from the American Cancer Society's Cancer Action Network in conjunction with the Association of Community Cancer Centers and the Oncology Nursing Society.  Click below to access the survey.

Click here for the survey

Walmart to Measure Doctor Quality in Local Markets
Walmart is rolling out an effort to measure the quality of community doctors who treat tens of thousands of its employees in the retailer’s latest effort to make sure its workers get the right care, in the right place and at the right time.

Find out more

Educate and Support Your Patients with ASCO Answers Materials
Recently, State Affiliate presidents and executive directors received a mailing from Cancer.Net that included patient education materials that you and your members may find useful. These materials, along with additional resources that can be found on Cancer.Net give your patients ASCO-approved information on diagnosis, treatment, side effects, and psychosocial effects of cancer.  The ASCO Answers series includes fact sheets, booklets on specific topics in cancer care, and comprehensive, patient-friendly guides. These easy-to-read materials cover breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, cancer survivorship, caregiving, palliative care, managing cancer-related pain, advanced cancer care planning, and much more.  ASCO members save 20 percent.  All orders include free domestic shipping. 

Order printed copies online at the ASCO Store.

August 2019 Advocacy Update

Click here for more.

Sharing Hospital Outpatient Payment Proposal Maintains 340B Cuts, Addresses Price Transparency and Prior Authorization
On July 29, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS) in 2020. ASCO is still analyzing the proposal and will provide more information to members as soon as possible.

Click here for more.

CMS Proposes New Electronic Prior Authorization Process to Speed Access to Care
CMS recently issued a proposed rule to update and streamline the prior authorization process under Medicare Part D.

Find out more